1Torok T J, Holman R C, Choba T L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data. 1968-1991. Am J Hematol,1995,50:84-90.
2Dang C T, Magid M S,Weksler B, et al. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood, 1999,93 :1264-1270.
3Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 1997,89: 3097- 3103.
4Tsai H M, Lian C Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med,1998,339:1585-1594.
5Remuzzi G, Galbusera M, Noris M, et al. yon Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood,2002,100: 778-785.
6Moore J C, Hayward C P M, Warkentin T E, et al.Decreased yon Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 2001,98:1842-1846.
7Bianchi V, Robles R, Alberio L, et al. yon Willebrand factor-Cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood,2002,100: 710-713.
8Gerritsen H E, Robles R, Lammie B, et al. Partial amino acid sequence of purified yon Willebrand factor-Cleaving protease. Blood, 2001,98 : 1654 - 1661.
9Zheng X, Chung D, Takayama T K,et al. Structure of von Willebrand factor-Cleaving protease(ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem, 2001,276:41059-41063.
10Elliott M A, Nichols W L. Thrombotic thromboeytopenic purpura, and hemolytic uremic syndrome. Mayo Clin Proc,2001,76: 1154-1162.
3NGUYEN T C, CARCILLO J A. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure-a newly appreciated syndrome in the critically ill[J].Clin Care, 2006,10 : 235- 241.
4DALAINAS I. Pathogenesis, diagnosis, and management of disseminated intravaseular eoagulation:a literature review[J]. Eur Rev Med Pharmacol Sci, 2008, 12:19-31.
5TSAI H M. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura[J]. J Am Soc Nephrol,2003,14:1072-1081.
7TAYLOR F B,TOH C H,HOOTS W K,et al. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Toward definition,clinical and laboratory criteria and scoring system for disseminated intravascular coagulation[J]. Thromb Haemost, 2001,86 : 1327 - 1330.
8THOM K A,SCHWEIZER M L,OSIH R B,et al. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study[J]. BMC Infect Dis, 2008,8:116-124.
9ONO T, MIMURO J, MADOIWA S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation:, its correlation with development of renal failure[J]. Blood, 2006,107:528-534.
